LAC Group uses cookies to improve functionality and performance of this site. More information can be found in our Privacy policy. By continuing to browse this site, you consent to the use of cookies.

Pharma CI Conference 2015: The importance of embedding CI in a company’s culture

September 14, 2015

Home Blog Pharma CI Conference 2015: The importance of embedding CI in a company’s culture

Competitive intelligence is a well-established addition to just about every pharma company’s strategic toolkit but, perhaps due to the clandestine associations of its name, it manages to operate mostly under the radar. At the 2015 Pharma CI Conference in Parsippany, N.J. on Sept. 10-11, practitioners, initiates and service providers for the CI functions backing many of the drug industry’s most powerful players – including Merck, Pfizer and Novartis – were front and center to share best practices, discuss industry innovations and challenges, and meet their peers.

Notable presentations and events included:

  • Michael Rowe, Allergan’s Executive Director of Corporate Strategic Intelligence, described how corporate intelligence involves analyzing and disseminating information, providing deep dives and anticipating the information needs of the leadership team;
  • Merck Executive Director and head of strategic business intelligence, Dr. Alfred A. Reszka, chaired a keynote panel of CI experts at companies outside the pharma industry. Participants highlighted the importance of scenario planning, having solid CI infrastructure and aligning different sources when providing insight; and
  • Pfizer’s Director of SPS Competitive Intelligence, Jessica Swartz, hosted a roundtable discussion on the role of CI in a world of information overload, in which participants shared best practices on how to filter out the noise from vast amount of information available via the Internet and other sources.

Experts from Teva, Upsher-Smith, Sanofi, Otsuka, EMD Serono, Shionogi, Ferring and many other major pharma players were also in attendance.

Top takeaways from the event:

  • Embedding CI in company culture: Many presentations at the event highlighted the importance, and difficulty, of not only establishing a CI capability within drug firms, but integrating it across these companies’ many and varied moving parts.
  • Insight is the top priority: The peripheral functions of CI, including primary research and information gathering, are so involved and time-consuming it can distract from the main point of any CI work – insight. Making these secondary efforts more efficient or farming them out to vendors gives CI teams more time to provide answers to the “So What?” questions that, if disseminated to the right people, help bulletproof companies against risk.
  • Innovation is integral to successful CI: Competitive intelligence is a well-established and vital business technique, but it can’t rest on its laurels. CI professionals need to remain flexible and adaptable to developments within their industry by continuously seeking new tools and techniques to refine their craft.

This article was originally published on ShiftCentral, now part of LAC Group.

Mario Thériault

Mario Thériault

Mario Thériault is Chief Business Development Officer and oversees all aspects of LAC Group’s growth strategy, partnership and alliance programs. Prior to LAC’s acquisition of ShiftCentral, Mario served as CEO and continuously evolved the company to emphasize the importance of strategic, curated intelligence to solve clients validated business needs.
Mario Thériault
Questions? Send me a message on our contact us form.

Related posts

Pharma CI experts bring insights to 2015 conference

Competitive intelligence professionals from Pfizer, Roche and Bayer are among the major pharmaceutical industry players who will give insight on…

Read more
LAC Group & Thomson Reuters partner with ARK Group for CI conference

Most law firms no longer question the need for competitive intelligence; what they do wonder is how to get it,…

Read more

Subscribe to our blog

Get notified when new articles are published.